WCN26-1729 Diagnostic performance of the creatinine-to-cystatin C based eGFR ratio for predicting sarcopenia in chronic kidney disease patients

Read full text Summarise with VIRAT
Authors: Nobuhiro Hashimoto, Miyu Tuchida, Syuzo Makino, Akito Takashima, Hiromitsu Miyakawa, Hiroki Okusima, Terumasa Hayashi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Sarcopenia, defined as a decrease in muscle mass and strength, is prevalent among patients with chronic kidney disease (CKD) and is associated with adverse clinical outcomes. The ratio of creatinine- to cystatin C-based eGFR (eGFRcre/eGFRcys) and the serum creatinine-to-cystatin C ratio (sCre/sCys), which account for the influence of muscle mass, have been reported to be associated with sarcopenia. However, data concerning advanced CKD are limited, and no study has specifically examined this association in Japanese patients with CKD.

Fields of Study & Subjects

Nutrition and Health in Aging Chronic Kidney Disease and Diabetes Dialysis and Renal Disease Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104682–104682
Publication date
25 March 2026
Language
EN